TY - JOUR
T1 - Abnormal neuronal response to rectal and anal stimuli in patients treated with primary radiotherapy for anal cancer
AU - Haas, Susanne
AU - Faaborg, Pia
AU - Gram, Mikkel
AU - Lundby, Lilli
AU - Brock, Christina
AU - Drewes, Asbjørn M.
AU - Laurberg, Søren
AU - Krogh, Klaus
AU - Christensen, Peter
PY - 2018
Y1 - 2018
N2 - Introduction: Sphincter-sparing radiotherapy or chemoradiation (RT/CRT) have become the standard treatments for most patients with anal cancer. Unfortunately, long-term survivors often suffer from severe bowel symptoms indicating sensory dysfunction. The aim of the present study was to characterize the sensory pathways of the brain–gut axis after radiotherapy for anal cancer. Method: Cortical evoked potentials (CEPs) were recorded during repeated, rapid balloon distensions of the rectum and anal canal in 13 patients with anal cancer treated with radiotherapy or chemoradiation and in 17 healthy volunteers. Latencies and amplitudes of rectal CEPs were compared between the groups. CEPs from both rectal and anal distensions were examined using single sweep spectral band analysis to determine the relative amplitude of five spectral bands as a proxy of neuronal processing. Results: Groups were comparable by age (62.4 ± 7.8 vs 58.9 ± 8.9, p < 0.32) and gender. Patients had a mean Wexner fecal incontinence score of 5.5 (±3.8) and median LARS Score of 29 (0–39). Rectal CEP latencies were prolonged in patients (F = 11.7; p < 0.001), whereas amplitudes were similar (F = 0.003; p = 0.96). Spectral analysis of CEPs from rectal distensions showed significant differences between groups in theta (4–8 Hz), alpha (8–12 Hz), beta (12–32 Hz) and gamma (32–70 Hz) bands (all p < 0.001) and CEPs from anal distensions showed significant differences in the alpha, beta and gamma bands (all p ≤ 0.002). Conclusion: Patients treated with RT/CRT for anal cancer have impaired ano-rectal sensory pathways and abnormal cortical processing. This may play a central role for the pathogenesis of late proctopathy.
AB - Introduction: Sphincter-sparing radiotherapy or chemoradiation (RT/CRT) have become the standard treatments for most patients with anal cancer. Unfortunately, long-term survivors often suffer from severe bowel symptoms indicating sensory dysfunction. The aim of the present study was to characterize the sensory pathways of the brain–gut axis after radiotherapy for anal cancer. Method: Cortical evoked potentials (CEPs) were recorded during repeated, rapid balloon distensions of the rectum and anal canal in 13 patients with anal cancer treated with radiotherapy or chemoradiation and in 17 healthy volunteers. Latencies and amplitudes of rectal CEPs were compared between the groups. CEPs from both rectal and anal distensions were examined using single sweep spectral band analysis to determine the relative amplitude of five spectral bands as a proxy of neuronal processing. Results: Groups were comparable by age (62.4 ± 7.8 vs 58.9 ± 8.9, p < 0.32) and gender. Patients had a mean Wexner fecal incontinence score of 5.5 (±3.8) and median LARS Score of 29 (0–39). Rectal CEP latencies were prolonged in patients (F = 11.7; p < 0.001), whereas amplitudes were similar (F = 0.003; p = 0.96). Spectral analysis of CEPs from rectal distensions showed significant differences between groups in theta (4–8 Hz), alpha (8–12 Hz), beta (12–32 Hz) and gamma (32–70 Hz) bands (all p < 0.001) and CEPs from anal distensions showed significant differences in the alpha, beta and gamma bands (all p ≤ 0.002). Conclusion: Patients treated with RT/CRT for anal cancer have impaired ano-rectal sensory pathways and abnormal cortical processing. This may play a central role for the pathogenesis of late proctopathy.
KW - Anal cancer
KW - Ano-rectal sensitivity
KW - Cortical processing
KW - Proctopathy
UR - http://www.scopus.com/inward/record.url?scp=85046127201&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2018.04.012
DO - 10.1016/j.radonc.2018.04.012
M3 - Journal article
SN - 0167-8140
VL - 128
SP - 369
EP - 374
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 2
ER -